Myeloperoxidase Polymorphism and Coronary Artery Disease Risk: A Meta-Analysis.

Yan Wang,Xu-Yan Chen,Ke Wang,Shan Li,Xiang-Yang Zhang
DOI: https://doi.org/10.1097/md.0000000000007280
IF: 1.6
2017-01-01
Medicine
Abstract:The myeloperoxidase (MPO) gene 463G/A and 129G/A polymorphisms have been reported to be associated with coronary artery disease (CAD), but the results remain inconclusive. This meta-analysis was designed to clarify these controversies.PubMed, EMBASE, and the Cochrane Library were used to retrieve the relevant literature up to March 2015 according to keywords. A total of 8 case-control studies, including 3491 cases and 7293 controls, were included in this meta-analysis. Summary odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were calculated.There was strong evidence of an association between the MPO 463G/A polymorphism and CAD. The data revealed that only the dominant model was associated with CAD (dominant model: OR = 0.872, 95% CI = 0.77-0.99). Regarding the 129G/A gene polymorphism, the pooled OR for the genotype AA + AG versus GG was 0.906 (95% CI = 0.74-1.10).This meta-analysis suggested an association between the MPO 463G/A polymorphism and the risk of CAD, but there is no significant association between the MPO 129G/A gene polymorphism and CAD risk.Abbreviations: A = adenine, CAC = coronary angiography-confirmed CAD, CAD = coronary artery disease, CI = confidence interval, G = guanine, HWE = Hardy-Weinberg equilibrium, MI = myocardial infarction, MPO = myeloperoxidase, OR = odds ratio, SNP = single-nucleotide polymorphism, SP1 = specificity protein 1.
What problem does this paper attempt to address?